Larimar Therapeutics, Inc. (LRMR )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol LRMR
- Company Larimar Therapeutics, Inc.
- Price $3.73
- Changes Percentage 32.56
- Change 0.92
- Day Low $3.55
- Day High $4.01
- Year High $5.37
- Year Low $1.61
- Market Cap $318,824,218
- Price Avg 50 EMA (D) $3.51
- Price Avg 200 EMA (D) $3.47
- Exchange NASDAQ
- Volume 63,535,140
- Average Volume 1,198,016
- Open $3.59
- Previous Close $2.81
- EPS -1.96
- PE -1.90
- Earnings Announcement 2026-03-30 13:30:00
- Shares Outstanding $85,590,394
Company brief: LARIMAR THERAPEUTICS, INC. (LRMR )
- Healthcare
- Biotechnology
- Dr. Carole S. Ben-Maimon M.D.
- https://www.larimartx.com
- US
- N/A
- 06-19-2014
- US5171251003
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.